Ávila-Nieto, Carlos
Vergara-Alert, Júlia
Amengual-Rigo, Pep
Ainsua-Enrich, Erola
Brustolin, Marco http://orcid.org/0000-0002-3594-4488
Rodríguez de la Concepción, María Luisa
Pedreño-Lopez, Núria http://orcid.org/0000-0001-6927-2301
Rodon, Jordi http://orcid.org/0000-0002-1032-9091
Urrea, Victor http://orcid.org/0000-0002-2577-856X
Pradenas, Edwards http://orcid.org/0000-0001-5162-8920
Marfil, Silvia
Ballana, Ester
Riveira-Muñoz, Eva
Pérez, Mònica
Roca, Núria
Tarrés-Freixas, Ferran
Cantero, Guillermo
Pons-Grífols, Anna http://orcid.org/0000-0002-8402-3941
Rovirosa, Carla
Aguilar-Gurrieri, Carmen http://orcid.org/0000-0002-5701-7650
Ortiz, Raquel
Barajas, Ana
Trinité, Benjamin http://orcid.org/0000-0003-3809-042X
Lepore, Rosalba
Muñoz-Basagoiti, Jordana http://orcid.org/0000-0002-0384-5928
Perez-Zsolt, Daniel http://orcid.org/0000-0003-4192-7622
Izquierdo-Useros, Nuria http://orcid.org/0000-0002-1039-1821
Valencia, Alfonso http://orcid.org/0000-0002-8937-6789
Blanco, Julià http://orcid.org/0000-0002-2225-0217
Guallar, Victor http://orcid.org/0000-0002-4580-1114
Clotet, Bonaventura http://orcid.org/0000-0003-3232-4598
Segalés, Joaquim http://orcid.org/0000-0002-1539-7261
Carrillo, Jorge http://orcid.org/0000-0003-0221-5948
Funding for this research was provided by:
Generalitat de Catalunya (SLD0015, 2020 FI_B_0742, 2020FI_B2_00138, 2022 FI_B_00698, SLD0016, 2021SGR00452)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI18/01332, PI17/01518)
Grifols Pharmaceutical support the present study Yomecorono was a crowdfunding project.
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (PID2020-117145RB-I00)
Grifols Pharmaceutical support the present study Yomecorono, BonePreu/Esclat, and Correos were crowdfunding projects.
Article History
Received: 21 April 2023
Accepted: 27 February 2024
First Online: 21 March 2024
Competing interests
: The present work counted on funding from Grifols pharmaceutical. However, Grifols had no role in study design, data analysis, decision to publish or manuscript preparation. P.A.R. is currently employed by Sanofi, which has no association with any content related to this work. The authors declare no other competing interests. Unrelated to the submitted work, J.B. and J.C. are founders and shareholders of AlbaJuna Therapeutics, S.L. B.C. is founder and shareholder of AlbaJuna Therapeutics, S.L. and AELIX Therapeutics, S.L, and V.G. is founder and shareholder of Nostrum Biodiscovery. Unrelated to the submitted work, N.I.-U. is supported by institutional funding from Pharma Mar, HIPRA, Amassence, and Palobiofarma.